ArticleFrontiers in endocrinology2026
Triglyceride-glucose index and subclinical left ventricular dysfunction across cardiovascular-kidney-metabolic syndrome stages: a 7-year retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose (TyG) index is associated with cardiovascular disease risk, but its role in identifying subclinical myocardial dysfunction and predicting heart failure (HF) in asymptomatic adults remains unclear. Objectives: To assess the association between TyG index and left ventricular global longitudinal strain (GLS), define a threshold for subclinical left ventricular dysfunction (SLVD), and evaluate its link to incident HF hospitalization. Methods: In this retrospective cohort study included, 4,784 asymptomatic adults aged 18-86 years from a Taiwan community and health check-up cohort without lipid-lowering therapy were included. SLVD was defined as GLS ≥-18%. Multivariable logistic and Cox regression analyses examined the relationship between TyG index, SLVD, and HF risk with covariates adjustment. Results: A TyG index ≥8.64 optimally discriminated individuals with SLVD, with an area under the receiver operating characteristic curve of 0.70. The prevalence of SLVD was 4.9% (130/2,656) among those with a normal TyG index and 12.9% (268/2,067) among those with an elevated TyG index. An elevated TyG index was independently associated with SLVD [odds ratio 1.62; 95% confidence interval (CI): 1.25-2.09], with stronger associations in those with stage B HF or cardiovascular-kidney-metabolic (CKM) syndrome. The proportion of individuals with an elevated TyG index increased markedly across CKM stages, from 3.5% (23/665) at stage 0 to 14.9% (148/991) at stage 1, 62.6% (1,849/2,955) at stage 2, and 42.0% (47/112) at stage 3. Over a median follow-up of 7.43 years, 61 participants experienced HF hospitalization. Individuals with both SLVD and a high TyG index had a substantially higher risk of HF hospitalization (hazard ratio 7.26; 95% CI: 3.44-15.35) compared with those without either condition. Conclusions: TyG index is a simple, accessible marker for early myocardial dysfunction and future HF risk, particularly when combined with SLVD or early-stage HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.